Active substances
Ethinylestradiol + Norgestimate
- SFDA 1
- US FDA 41
- Health Canada 6
- US price lines 10
- NHS prices 1
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| CILEST TAB | 0.035, 0.250 mg | Tablet · Oral use | 21 Blister | SAR 16.50 | NCE · Prescription | Janssen-Cilag International NV | Withdrawn by MAH · Not Marketed |
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| SPRINTEC | 0.035MG;0.25MG | tablet · oral-28 | BARR | Prescription | 25 Sep 2002 |
| TRI-SPRINTEC | 0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,0.25MG | tablet · oral-28 | BARR | Prescription | 29 Dec 2003 |
| ORTHO TRI-CYCLEN 21 | 0.035MG,0.035MG,0.035MG; 0.18MG,0.215MG,0.25MG | tablet · oral-21 | ORTHO MCNEIL PHARM | Prescription | 13 May 2005 |
| ORTHO TRI-CYCLEN 28 | 0.035MG,0.035MG,0.035MG; 0.18MG,0.215MG,0.25MG | tablet · oral-28 | ORTHO MCNEIL PHARM | Prescription | 13 May 2005 |
| TRI LO SPRINTEC | 0.025MG,0.025MG,0.025MG;0.18MG,0.215MG,0.25MG | tablet · oral-28 | BARR LABS INC | Prescription | 29 Jun 2009 |
| NORGESTIMATE; ETHINYL ESTRADIOL | 0.215MG; 0.025MG; 0.25MG; 0.025MG | tablet · oral | WATSON LABS | Prescription | 9 Mar 2011 |
| NORGESTIMATE AND ETHINYL ESTRADIOL | 0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,0.25MG | tablet · oral-28 | GLENMARK PHARMS LTD | Prescription | 17 Jun 2011 |
| NORGESTIMATE; ETHINYL ESTRADIOL | 0.215MG; 0.035MG; 0.25MG; 0.035MG | tablet · oral | GLENMARK PHARMS LTD | Prescription | 17 Jun 2011 |
| NORGESTIMATE AND ETHINYL ESTRADIOL | 0.035MG;0.25MG | tablet · oral-28 | GLENMARK PHARMS LTD | Prescription | 5 Apr 2012 |
| MONO-LINYAH | 0.035MG;0.25MG | tablet · oral-28 | NOVAST LABS LTD | Prescription | 23 May 2012 |
| TRI-LINYAH | 0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,0.25MG | tablet · oral-28 | NOVAST LABS LTD | Prescription | 30 May 2012 |
| NORGESTIMATE AND ETHINYL ESTRADIOL | 0.025MG,0.025MG,0.025MG;0.18MG,0.215MG,0.25MG | tablet · oral-28 | LUPIN PHARMS | Prescription | 25 Jun 2012 |
| TRI-ESTARYLLA | 0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,0.25MG | tablet · oral-28 | XIROMED | Prescription | 30 Jan 2013 |
| ESTARYLLA | 0.035MG;0.25MG | tablet · oral-28 | XIROMED | Prescription | 30 Jan 2013 |
| NORGESTIMATE AND ETHINYL ESTRADIOL | 0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,0.25MG | tablet · oral-28 | NAARI PTE | Prescription | 7 Apr 2015 |
| NORGESTIMATE AND ETHINYL ESTRADIOL | 0.035MG;0.25MG | tablet · oral-28 | NAARI PTE | Prescription | 7 Apr 2015 |
| TRI-LO-ESTARYLLA | 0.025MG,0.025MG,0.025MG;0.18MG,0.215MG,0.25MG | tablet · oral-28 | XIROMED | Prescription | 29 Jun 2015 |
| NORGESTIMATE AND ETHINYL ESTRADIOL | 0.025MG,0.025MG,0.025MG;0.18MG,0.215MG,0.25MG | tablet · oral-28 | GLENMARK SPECLT | Prescription | 23 Feb 2016 |
| NORGESTIMATE AND ETHINYL ESTRADIOL | 0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,0.25MG | tablet · oral-28 | LUPIN | Prescription | 26 Apr 2016 |
| NORGESTIMATE AND ETHINYL ESTRADIOL | 0.025MG,0.025MG,0.025MG;0.18MG,0.215MG,0.25MG | tablet · oral-28 | NAARI PTE | Prescription | 12 May 2016 |
| TRI-MILI | 0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,0.25MG | tablet · oral-28 | AUROBINDO PHARMA LTD | Prescription | 6 Jul 2016 |
| MILI | 0.035MG;0.25MG | tablet · oral-28 | AUROBINDO PHARMA LTD | Prescription | 7 Jul 2016 |
| NORGESTIMATE AND ETHINYL ESTRADIOL | 0.035MG;0.25MG | tablet · oral-28 | LUPIN | Prescription | 27 Oct 2016 |
| TRI-LO-MILI | 0.025MG,0.025MG,0.025MG;0.18MG,0.215MG,0.25MG | tablet · oral-28 | AUROBINDO PHARMA | Prescription | 4 Nov 2016 |
| TRI-LO-LINYAH | 0.025MG,0.025MG,0.025MG;0.18MG,0.215MG,0.25MG | tablet · oral-28 | NOVAST LABS | Prescription | 2 Sep 2022 |
16 more — full table
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| TRI-CIRA 21 | 02508087 | 0.215 MG; 0.035 MG; 0.25 MG; 0.18 MG | TABLET · ORAL | APOTEX INC |
| TRI-CIRA 28 | 02508095 | 0.035 MG; 0.18 MG; 0.215 MG; 0.25 MG | TABLET · ORAL | APOTEX INC |
| TRI-CIRA LO 21 | 02401967 | 0.025 MG; 0.25 MG; 0.215 MG; 0.18 MG | TABLET · ORAL | APOTEX INC |
| TRI-CIRA LO 28 | 02401975 | 0.025 MG; 0.25 MG; 0.18 MG; 0.215 MG | TABLET · ORAL | APOTEX INC |
| TRI-JORDYNA 21 | 02486296 | 0.035 MG; 0.18 MG; 0.25 MG; 0.215 MG | TABLET · ORAL | GLENMARK PHARMACEUTICALS CANADA INC. |
| TRI-JORDYNA 28 | 02486318 | 0.035 MG; 0.215 MG; 0.18 MG; 0.25 MG | TABLET · ORAL | GLENMARK PHARMACEUTICALS CANADA INC. |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | ESTARYLLA 0.25-0.035 MG TABLET | $0.11481 | per EA | 23 Sep 2026 |
| US NADAC | MILI 0.25-0.035 MG TABLET | $0.11481 | per EA | 23 Sep 2026 |
| US NADAC | SPRINTEC 28 DAY TABLET | $0.11481 | per EA | 23 Sep 2026 |
| US NADAC | TRI-ESTARYLLA TABLET | $0.12642 | per EA | 23 Sep 2026 |
| US NADAC | TRI-LINYAH TABLET | $0.12642 | per EA | 23 Sep 2026 |
| US NADAC | TRI-LO-ESTARYLLA TABLET | $0.10804 | per EA | 23 Sep 2026 |
| US NADAC | TRI-LO-MILI TABLET | $0.10804 | per EA | 23 Sep 2026 |
| US NADAC | TRI-LO-SPRINTEC TABLET | $0.10804 | per EA | 23 Sep 2026 |
| US NADAC | TRI-MILI 28 TABLET | $0.12642 | per EA | 23 Sep 2026 |
| US NADAC | TRI-SPRINTEC TABLET | $0.12642 | per EA | 23 Sep 2026 |
| NHS Drug Tariff | Ethinylestradiol 35microgram / Norgestimate 250microgram tablets | £4.65 | 63 tablet | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Components
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.